BDRX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

-31.23%

1 Month

-59.50%

3 Months

-53.33%

6 Months

375.73%

1 Year

54.33%

2 Year

-98.36%

Key data

Stock price

$1.96

P/E Ratio

0.00

DAY RANGE

$1.90 - $2.32

EPS

N/A

52 WEEK RANGE

$0.23 - $10.89

52 WEEK CHANGE

$73.45

MARKET CAP

36.295 K

YIELD

N/A

SHARES OUTSTANDING

14.521 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

4.76

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,457,072

AVERAGE 30 VOLUME

$1,481,585

Company detail

CEO: Stephen A. Stamp
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: 2015

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Midatech Pharma plc focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. MTX114, an immuno-suppressant for topical application in psoriasis, MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder.

BDRX - Biodexa Pharmaceuticals Plc